Profile data is unavailable for this security.
About the company
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
- Revenue in USD (TTM)112.25m
- Net income in USD-3.42m
- Incorporated2000
- Employees391.00
- LocationHarvard Bioscience Inc84 OCTOBER HILL RDHOLLISTON 01746United StatesUSA
- Phone+1 (508) 893-8999
- Fax+1 (508) 429-5732
- Websitehttps://www.harvardbioscience.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Babcock & Wilcox Enterprises Inc | 999.35m | -93.73m | 91.27m | 2.20k | -- | -- | -- | 0.0913 | -1.05 | -2.38 | 11.22 | -2.25 | 1.16 | 7.16 | 5.30 | 454,251.80 | -9.16 | -5.50 | -15.81 | -11.87 | 22.42 | 22.90 | -7.87 | -5.30 | 1.10 | 0.5061 | 1.97 | -- | 17.86 | -1.22 | -201.13 | -- | 12.36 | -- |
| Seer Inc | 16.66m | -86.28m | 134.73m | 147.00 | -- | 0.337 | -- | 8.09 | -1.35 | -1.35 | 0.2609 | 6.17 | 0.0361 | 1.79 | 2.43 | 113,340.10 | -18.67 | -16.65 | -19.21 | -17.09 | 51.05 | -- | -517.84 | -756.71 | 24.66 | -- | 0.00 | -- | 7.54 | -- | 7.20 | -- | 112.67 | -- |
| Geospace Technologies Corp | 143.43m | 24.98m | 161.80m | 681.00 | 6.50 | 1.11 | 3.94 | 1.13 | 1.87 | 1.87 | 10.76 | 10.99 | 0.938 | 3.76 | 4.35 | 210,619.70 | 16.34 | -5.10 | 18.55 | -5.54 | 44.20 | 28.70 | 17.42 | -8.96 | 3.79 | -- | 0.00 | -- | 39.50 | 10.45 | 153.40 | -- | 11.01 | -- |
| Harvard Bioscience, Inc. | 112.25m | -3.42m | 165.87m | 391.00 | -- | 2.27 | 46.29 | 1.48 | -0.0803 | -0.0803 | 2.63 | 1.68 | 0.7941 | 1.81 | 6.84 | 287,084.40 | -2.42 | -3.29 | -2.93 | -3.89 | 58.86 | 56.67 | -3.04 | -4.57 | 0.9164 | 0.4485 | 0.3335 | -- | -0.9573 | -1.45 | 64.11 | -- | 18.10 | -- |
| Northern Technologies International Corp | 82.70m | 3.66m | 166.87m | 86.00 | 46.93 | 2.44 | 24.40 | 2.02 | 0.3772 | 0.3772 | 8.61 | 7.25 | 0.9537 | 3.76 | 5.27 | 961,669.60 | 5.88 | 6.29 | 7.44 | 7.71 | 37.01 | 33.21 | 6.16 | 7.42 | 1.86 | -- | 0.0524 | 53.37 | 7.75 | 9.21 | -53.95 | -16.87 | 34.39 | 13.30 |
| Virtra Inc | 38.04m | 8.40m | 175.09m | 112.00 | 20.59 | 4.11 | 18.76 | 4.60 | 0.7653 | 0.7653 | 3.47 | 3.84 | 0.6163 | 1.03 | 2.78 | 339,672.80 | 13.61 | 7.69 | 17.16 | 9.70 | 70.09 | 59.06 | 22.09 | 11.12 | 2.32 | -- | 0.1587 | -- | 34.42 | 16.04 | 329.62 | 59.34 | 30.96 | -- |
| 908 Devices Inc. | 50.23m | -36.40m | 187.59m | 230.00 | -- | 1.12 | -- | 3.73 | -1.13 | -1.13 | 1.56 | 5.09 | 0.2255 | 1.81 | 5.28 | 218,387.00 | -16.34 | -14.16 | -18.03 | -15.35 | 50.41 | 53.02 | -72.47 | -64.25 | 7.04 | -- | 0.00 | -- | 7.21 | 17.89 | -8.45 | -- | 22.98 | -- |
| Holder | Shares | % Held |
|---|---|---|
| 272 Capital LPas of 31 Dec 2023 | 2.94m | 6.77% |
| Punch & Associates Investment Management, Inc.as of 31 Dec 2023 | 2.92m | 6.72% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.69m | 6.20% |
| Harvey Partners LLCas of 31 Dec 2023 | 2.56m | 5.89% |
| AMH Equity Ltd.as of 18 Mar 2024 | 2.31m | 5.32% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.02m | 4.66% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 1.93m | 4.44% |
| Granahan Investment Management, LLCas of 31 Dec 2023 | 1.84m | 4.25% |
| Royce & Associates LPas of 31 Dec 2023 | 1.45m | 3.34% |
| Boothbay Fund Management LLCas of 31 Dec 2023 | 1.36m | 3.14% |
